Novo Nordisk's Victoza Gains First Japanese GLP-1 Approval
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk announced Jan. 20 it received approval for Victoza (liraglutide) from Japan's Ministry of Health, Labor and Welfare for type 2 diabetes and hopes to launch Japan's first glucagon-like peptide-1 agonist in the first half of 2010 - pending pricing negotiations for National Health Insurance reimbursement